BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 36847930)

  • 1. Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer's Disease.
    Rani S; Dhar SB; Khajuria A; Gupta D; Jaiswal PK; Singla N; Kaur M; Singh G; Barnwal RP
    Cell Mol Neurobiol; 2023 Aug; 43(6):2491-2523. PubMed ID: 36847930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer's disease.
    Park SA; Han SM; Kim CE
    Exp Mol Med; 2020 Apr; 52(4):556-568. PubMed ID: 32284537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
    Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP
    Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for Alzheimer's disease: current status and prospects for the future.
    Blennow K; Zetterberg H
    J Intern Med; 2018 Dec; 284(6):643-663. PubMed ID: 30051512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease.
    Mattsson N; Insel PS; Palmqvist S; Portelius E; Zetterberg H; Weiner M; Blennow K; Hansson O;
    EMBO Mol Med; 2016 Oct; 8(10):1184-1196. PubMed ID: 27534871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the development paradigm of biosample-based biosensors for early ultrasensitive detection of alzheimer's disease.
    Karki HP; Jang Y; Jung J; Oh J
    J Nanobiotechnology; 2021 Mar; 19(1):72. PubMed ID: 33750392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic.
    Paterson RW; Slattery CF; Poole T; Nicholas JM; Magdalinou NK; Toombs J; Chapman MD; Lunn MP; Heslegrave AJ; Foiani MS; Weston PSJ; Keshavan A; Rohrer JD; Rossor MN; Warren JD; Mummery CJ; Blennow K; Fox NC; Zetterberg H; Schott JM
    Alzheimers Res Ther; 2018 Mar; 10(1):32. PubMed ID: 29558979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease.
    Alawode DOT; Heslegrave AJ; Ashton NJ; Karikari TK; Simrén J; Montoliu-Gaya L; Pannee J; O Connor A; Weston PSJ; Lantero-Rodriguez J; Keshavan A; Snellman A; Gobom J; Paterson RW; Schott JM; Blennow K; Fox NC; Zetterberg H
    J Intern Med; 2021 Sep; 290(3):583-601. PubMed ID: 34021943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease.
    Pereira JB; Westman E; Hansson O;
    Neurobiol Aging; 2017 Oct; 58():14-29. PubMed ID: 28692877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease.
    Grau-Rivera O; Navalpotro-Gomez I; Sánchez-Benavides G; Suárez-Calvet M; Milà-Alomà M; Arenaza-Urquijo EM; Salvadó G; Sala-Vila A; Shekari M; González-de-Echávarri JM; Minguillón C; Niñerola-Baizán A; Perissinotti A; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Gispert JD; Molinuevo JL;
    Alzheimers Res Ther; 2021 Feb; 13(1):46. PubMed ID: 33597012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease.
    Engelborghs S; Le Bastard N
    Mol Diagn Ther; 2012 Jun; 16(3):135-41. PubMed ID: 22646065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease.
    Prvulovic D; Hampel H
    Clin Chem Lab Med; 2011 Mar; 49(3):367-74. PubMed ID: 21342022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological markers of Alzheimer's disease.
    de Souza LC; Sarazin M; Teixeira-Júnior AL; Caramelli P; Santos AE; Dubois B
    Arq Neuropsiquiatr; 2014 Mar; 72(3):227-31. PubMed ID: 24676441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging Techniques in Alzheimer's Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring.
    van Oostveen WM; de Lange ECM
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of the blood biomarkers in Alzheimer's disease: Promises and challenges.
    Delaby C; Hirtz C; Lehmann S
    Rev Neurol (Paris); 2023 Mar; 179(3):161-172. PubMed ID: 36371265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings.
    Blennow K; Zetterberg H
    Prog Mol Biol Transl Sci; 2019; 168():3-23. PubMed ID: 31699324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.